Stablepharma announce another new recruit to the Science team in Madrid, Spain based at Stablepharma’s R&D Center of Excellence (CoE) in Qube Technology Park
Data shows powerful synergy in combination with standard cancer treatments
I am looking forward to our first in-person events of 2022 this week, headlined by the BIA’s Annual Gala Dinner. This is a chance to celebrate the fantastic work undertaken by the sector throughout 2021 and raise money for our Charity Partner of the Year, Kidney Research UK. There are a few individual tickets left, so do book quickly if you are interested in attending.
A team of virologists move to Discovery Park to expand operations. Demand for lab and manufacturing space continues at Discovery Park to support the UK’s booming life science industry.
This cell culture supplement can be used to manufacture both autologous and allogeneic cell therapies.
The National Institute for Health and Care Excellence (NICE) has published its conclusions to its review of its methods and processes for Health Technology Assessments.
Dr Ruth McKernan CBE, former chair of the BioIndustry Association and former Chair of Innovate UK, discusses the future of antivirals in relation to COVID-19 and how this works with current government processes.
First patient dosed in potential game-changing diabetes combination therapy
New role enables accelerated delivery of buildings for existing & new occupiers
Pneumagen is a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs).